|Bid||31.95 x 900|
|Ask||33.20 x 800|
|Day's Range||31.95 - 33.55|
|52 Week Range||16.04 - 33.55|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||1,468.18|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 13.) Arvinas Inc (NASDAQ: ARVN ) Baxter International ...
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
Anyone interested in NeoGenomics, Inc. (NASDAQ:NEO) should probably be aware that the President of Clinical Services...
NeoGenomics (NEO) delivered earnings and revenue surprises of 16.67% and 5.50%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of June 28. The results of that effort will be put on display in this article, as […]
NeoGenomics, Inc. (NASDAQ:NEO), which is in the life sciences business, and is based in United States, saw significant...
NeoGenomics, Inc. (NASDAQ:NEO) shareholders have seen the share price descend 14% over the month. But in stark...
During Friday's Lightning Round of Mad Money one caller asked about the Fort Meyers, FL headquartered NeoGenomics : "I won't say no to anyone working to cure cancer," replied Jim Cramer. NeoGenomics is a clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. In this daily bar chart of NEO, below, we can see that prices more than doubled this calendar year.
NeoGenomics stock is the IBD Stock Of The Day as the cancer-testing outlet breaks out on a never-higher relative strength line. Earlier this week, NeoGenomics posted a quarterly beat.
NeoGenomics (NEO) delivered earnings and revenue surprises of 0.00% and 5.03%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cancer testing firm NeoGenomics broke out Thursday from a flat base, a couple of days after reporting strong earnings. NEO is stock of the day. Many cancer-testing firms are doing well.STOCK MARKET TODAY is sponsored by Interactive Brokers. To open an account, go to ibkr.com/whyib